ArticleBlood advances2022

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.

Haesook T Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.